International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

Intellectual Property and the Pandemic: Balancing Innovation and Access

Sayantani Ray [Author][1], Rifa Naseer [Co-Author][2]
[1,2]*Assistant Professor, School of Law, Chettinad Academy of Research and Education, India*

Abstract **– The COVID-19 pandemic has profoundly catalyst the discourse on Intellectual Property and public health which underscores the need to achieve a balanced framework between equitable access and innovation to essential medicines. The paper examines critically the influence of IP rights particularly patents, copyrights, and trade secrets in development, production, and global distribution of life-saving medical technologies during public health emergencies. The inherent conflict between safeguarding inventors' rights and ensuring the fundamental right to health, especially for low- and middle-income nations has been highlighted.**

In India's perspective, the paper dives into the country's distinctive stance to reconcile IP protection with public health perspectives. India's experience with compulsory licensing, its control in vaccine development and manufacturing, and contribution in international alliances such as COVAX and the TRIPS waiver initiative exemplify its commitment to equitable access. Further, assesses the global IP governance framework through instruments like the WTO's TRIPS Agreement, the Doha Declaration on TRIPS and Public Health, and the role of the World Health Organization (WHO) in promoting international solidarity.

The paper concludes that while intellectual property protection is essential to sustain innovation and entice investment, rigid enforcement during global crises can obstruct the timely distribution of such life-saving medical technologies. A transformative and flexible IP regime, grounded in the principles of cooperation, shared responsibility, and global equity, is essential for future pandemic resilience. True innovation, it argues, must ultimately be measured by its capacity to serve humanity rather than profit alone.

Keywords **– Intellectual Property, TRIPS Agreement, Compulsory Licensing, Vaccine Nationalism, Public Health, Pandemic Response, India, Global Access, WHO, Innovation Policy.**

I. Introduction

The intersection of Intellectual Property (IP) and Pandemic response has become a prominent topic in the global public health discourse, with the ongoing COVID-19 pandemic serving as a catalyst for intense discussions. The COVID-19 crisis has underscored the need to strike a delicate balance between safeguarding IP rights and ensuring timely, equitable access to essential medical innovations.

This complex relationship raises critical questions and challenges, especially in the context of India, a nation renowned for its pharmaceutical industry and commitment to global public health.

India's perspective on IP and pandemic response is of particular significance due to its multifaceted approach. The nation's robust pharmaceutical industry, history of compulsory licensing, active participation in international collaborations, and leadership in vaccine development embody its vision of shared responsibility and global solidarity. However, the Indian perspective also navigates challenges such as vaccine nationalism, the need to balance IP protection with public health imperatives, and the complexities of global supply chains.

It highlights the global impact of India's contributions, the role of innovation and investment, the importance of knowledge transfer, and the necessity of finding a balance between vaccine nationalism and underscoring the significance of global collaboration and shared responsibility in safeguarding public health on a global scale.

II. Meaning And Concept Of Intellectual Property In The Context Of A Pandemic

The COVID-19 pandemic has profoundly impacted societies and economies worldwide, necessitating a re-evaluation of various facets of public health, international cooperation, and Intellectual Property (IP) rights. The relationship between IP and pandemics, including the meaning and concept of IP in this context, has become a subject of heightened scrutiny. This section explores the significance of IP, its underlying principles, and the challenges it poses in a pandemic, emphasising the need to reconcile the needs of public health with IP protection.

A. Understanding Intellectual Property

Intellectual property is a legal concept encompassing a range of intangible assets created by human intellect and innovation. It primarily consists of four key components: patents, copyrights, trademarks, and trade secrets[i]. These forms of IP protection grant creators, inventors, and organizations exclusive rights over their intellectual creations, allowing them to control the use, distribution, and commercial exploitation of these creations.

International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

Patents safeguard new inventions, granting the inventor exclusive rights to make, use, and sell the invention for a specified period[ii]. In the realm of pandemics, this can encompass pharmaceuticals, vaccines, diagnostic tools, and medical devices. Copyrights protect literary, artistic, and musical works[iii]. During a pandemic, this may involve protecting intellectual creations such as scientific research, clinical trial data, and medical literature.

Further, Trademarks protect distinctive signs, logos, and symbols used to distinguish products or services[iv]. In the context of a pandemic, trademarks are critical for branding and identifying pharmaceuticals and medical equipment. ln the context of Trade secrets safeguards confidential business information and processes[v]. This can include proprietary formulas, manufacturing methods, or clinical trial results that are essential for the development of medical solutions.

B. The Significance of Intellectual Property in a Pandemic

IP protection incentivizes innovation by ensuring that creators and inventors have the potential to benefit financially from their work[vi]. It promotes funding for scientific research and creation of novel drugs, therapies, and vaccinations during a pandemic. IP rights can facilitate collaboration between researchers, institutions, and pharmaceutical companies[vii]. Licensing agreements and partnerships are often necessary to bring a new medical solution to market, and IP rights help structure these collaborations. Whereas, Trademarks and Patents play a vital role in quality control and ensuring the safety and efficacy of medical products[viii]. By allowing manufacturers to protect their brand reputation, consumers can have confidence in the products they use. IP protection, when used judiciously, can encourage market competition[ix]. It allows multiple companies to vie for the development of similar products, potentially leading to improved options for consumers.

The pandemic has highlighted the need for equitable access to medical solutions, which can be hampered by IP restrictions[x]. High licensing costs and exclusive rights can limit accessibility, particularly in lower-income countries. The race to secure vaccines has sometimes been characterised by "vaccine nationalism," with governments prioritising their citizens over global cooperation[xi]. This approach can disrupt the equitable distribution of vaccines. Some nations have implemented emergency measures in reaction to the epidemic, temporarily suspending or waiving certain intellectual property rights[xii]. This has sparked debates about the necessity and potential consequences of such measures.

IP protection can sometimes hinder international collaboration[xiii]. Disputes over patents and proprietary information can impede the rapid sharing of knowledge and resources necessary to combat a pandemic.

III. The Role Of International Agreements And Organizations

The way that intellectual property and pandemics interact is greatly influenced by international agreements and organizations. The World Trade Organization (WTO) developed the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which serves as a major framework for IP protection internationally[xiv]. TRIPS sets the standards for IP protection and provides flexibility for countries to take measures in the interest of public health, as seen in the Doha Declaration[xv]. This declaration emphasises the ability of countries to issue compulsory licences and make use of flexibilities under TRIPS in cases of public health emergencies.

The World Health Organization (WHO), in addition to TRIPS, is essential in directing international health efforts during pandemics[xvi]. The WHO advocates for increased access to essential medical technologies and the fair distribution of vaccines, treatments, and diagnostic tools. These organisations serve as platforms for international collaboration and negotiations on IP and public health issues.

IV. International Scenario: Intellectual Property (IP) And Pandemic Response

Public health faces hitherto unheard-of difficulties as a result of the global COVID-19 pandemic, underscoring the importance of equitable access to medical innovations. In this context, the international scenario regarding Intellectual Property (IP) and the pandemic has become a focal point of discussion. International agreements, organisations, and collaborative efforts have been instrumental in shaping how nations navigate the complex relationship between the necessity of timely and reasonably priced access to critical healthcare solutions and IP protection.

A. International Agreements and Intellectual Property

At the heart of the international scenario concerning IP and pandemics lies the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), established by the World Trade Organization (WTO)[xvii]. TRIPS sets the global standards for IP protection, encompassing patents, copyrights, trademarks, and trade secrets. Its framework is instrumental in regulating the use of IP rights, particularly in the context of public health emergencies.

International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

The TRIPS Agreement recognizes the importance of striking a balance between IP protection and public health. This balance is exemplified by the Doha Declaration on the TRIPS Agreement and Public Health, which was adopted in 2001[xviii]. The statement made it clear that TRIPS should be read and used in a way that permits nations to take the actions required to safeguard public health. These measures include issuing compulsory licences and utilising TRIPS flexibilities to ensure access to affordable medicines during health crises, such as a pandemic.

B. The Role of the World Health Organization (WHO)

The World Health Organization (WHO) plays a pivotal role in coordinating international efforts during pandemics[xix]. Although the WHO does not directly regulate intellectual property, it plays a significant role in promoting fair access to medical advancements such as therapies, vaccinations, and diagnostic instruments.

During the COVID-19 pandemic, the WHO has emphasised the importance of global collaboration and the fair distribution of medical solutions. This dedication is demonstrated by the WHO's COVAX effort, which attempts to guarantee fair access to COVID-19 vaccinations for all nations[xx]. The initiative recognizes that IP-related issues, such as vaccine production and distribution, must be addressed comprehensively to meet the demands of a pandemic.

C. International Collaboration and Access Initiatives

The international scenario also involves a multitude of collaborative efforts aimed at addressing IP-related challenges during the pandemic. These activities emphasize the acknowledgment by the international community that, while dealing with a public health emergency, managing intellectual property (IP) and guaranteeing fair access to medical remedies is a collective obligation. The Access to COVID-19 Tools (ACT) Accelerator, initiated by the World Health Organization (WHO) and its international collaborators, aims to ensure equitable availability of COVID-19 vaccines, therapies, and diagnostic tools[xxi]. It acknowledges the significance of IP issues in pandemic response and is committed to ensuring that IP barriers do not hinder access to medical innovations.

The COVID-19 Technology Access Pool (C-TAP) is a program endorsed by the World Health Organization (WHO) that aims to promote the voluntary exchange of intellectual property (IP), expertise, and data pertaining to technologies used in the fight against COVID-19[xxii]. It strives to create a repository of information and technology that can be accessed and used by countries and organisations for the development of COVID-19 solutions.

In October 2020, India and South Africa recommended a temporary exemption on specified parts of the TRIPS Agreement pertaining to intellectual property (IP) rights, including patents and trade secrets, for medical products related to COVID-19[xxiii]. The proposal seeks to guarantee that intellectual property (IP) does not impede the equitable distribution and scaling up of COVID-19 vaccine and treatment production, particularly in low- and middle-income countries.

While international agreements, organisations, and collaborative initiatives have made progress in addressing the complex relationship between IP and pandemics, challenges and debates persist. These challenges reflect the tension between IP protection and the urgency of providing accessible medical solutions during a pandemic. The pandemic has revealed disparities in global vaccine distribution, often referred to as "vaccine nationalism," where some countries prioritise their own populations over international cooperation[xxiv]. This problem emphasizes the necessity of global initiatives to guarantee fair access to immunizations and medical care.

Some countries have adopted emergency measures that temporarily suspend or waive certain IP rights to address the urgency of the pandemic[xxv]. The necessity and potential consequences of such measures have been subjects of debate. Ensuring access to medical solutions during a pandemic involves complex global supply chains[xxvi]. These supply chains may include the transfer of knowledge and technology, raising questions about the role of IP in facilitating or hindering these transfers.

V. Indian Perspective: Intellectual Property And Pandemic Response

The COVID-19 pandemic has presented a challenge to states in balancing the need to guarantee worldwide access to critical medical discoveries with the preservation of Intellectual Property (IP) rights. India, with its burgeoning pharmaceutical industry and a long history of grappling with issues of access to medicines, provides a unique perspective on the intersection of IP and pandemic response. This section explores the Indian perspective on IP in the context of the pandemic, emphasising the nation's experiences, policies, and contributions to global public health.

A. India's Pharmaceutical Industry And Generic Medicines

India has a robust pharmaceutical industry and is often referred to as the "pharmacy of the world" production of generic medicines. The country's pharmaceutical firms have been instrumental in providing the world's population with access to reasonably priced medications, particularly in low- and middle-income nations.

International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

India's IP policies and legal framework have supported the growth of its pharmaceutical sector, emphasising a balance between IP protection and public health needs[xxvii].

In the context of the pandemic, India's pharmaceutical industry has been instrumental in producing generic versions of drugs and vaccines related to COVID-19. This includes the production of hydroxychloroquine, remedies, and COVID-19 vaccines, contributing to the global effort to ensure access to medical solutions. India's ability to manufacture these medicines at a lower cost has been a game-changer, particularly for countries facing resource constraints[xxviii].

B. Compulsory Licensing: India's Experience

One of the standout aspects of the Indian perspective on IP during a pandemic is the nation's experience with compulsory licensing. India has issued compulsory licences for pharmaceutical products in the past, most notably in the case of Bayer's cancer drug Nexavar in 2012[xxix]. The issuance of a compulsory licence allowed Indian generic manufacturers to produce the drug at a significantly lower cost, expanding access to life-saving treatment.

In the context of the COVID-19 pandemic, India's regulatory framework provides the flexibility to issue compulsory licences for medical innovations when necessary to address public health concerns[xxx]. While India has not yet issued compulsory licences specifically for COVID-19- related products, the legal foundation for such action exists, and the possibility remains a part of India's toolkit to ensure access to essential medical solutions.

C. International Collaborations And Access Initiatives

India has actively engaged in international collaborations and access initiatives, aligning with its perspective on the importance of global access to medical solutions during a pandemic. An exemplary endeavor is India's involvement in the World Health Organization's (WHO) COVAX program, which strives to provide fair and impartial availability of COVID-19 vaccinations to all nations[xxxi]. This initiative reflects India's commitment to making vaccines accessible and affordable worldwide, emphasising that access to vaccines is a global public good.

India has also supported the COVAX initiative by contributing to the global supply of COVID-19 vaccines. The country, known for its vaccine manufacturing capacity, has been a key player in producing vaccines like AstraZeneca's Covishield, contributing to the initiative's goal of distributing vaccines to low- and middle-income countries[xxxii].

D. India's Leadership In Vaccine Development

The pandemic has highlighted India's leadership in vaccine development. Indian pharmaceutical companies, including Bharat Biotech, Serum Institute of India, and Dr. Reddy's Laboratories, have been actively involved in COVID-19 vaccine research, development, and manufacturing. Covaxin, developed by Bharat Biotech, and Covishield, produced by the Serum Institute of India under a licensing agreement with AstraZeneca, are two prominent examples[xxxiii].

India's role in vaccine development aligns with its commitment to ensuring global access to vaccines. This perspective reflects a sense of shared responsibility, where India's expertise in vaccine production can contribute to addressing the global vaccination gap and assisting other countries in their pandemic response. While India's perspective on IP and pandemics emphasises the importance of equitable access to medicines, challenges and debates persist. One notable challenge is the issue of "vaccine nationalism," where countries prioritise their own populations over global collaboration[xxxiv]. This approach can disrupt the equitable distribution of vaccines and hinder international cooperation.

Another challenge is the delicate balance between IP protection and access to essential medical solutions. India has faced criticism from some multinational pharmaceutical companies for its approach to compulsory licensing and patent challenges[xxxv]. These debates underscore the complexity of striking a balance between IP rights and public health needs during a pandemic.

E. Impact on Innovation and Investment

India's stance on compulsory licensing and its readiness to grant such licenses when deemed necessary have sparked worries regarding their potential ramifications on innovation and investment within the pharmaceutical industry. Multinational pharmaceutical companies argue that these measures can undermine the incentive for research and development. They claim that if companies believe their patents can be easily overridden through compulsory licensing, it might deter them from investing in research to develop new drugs and vaccines[xxxvi].

This underscores a fundamental conflict between the necessity to encourage innovation, typically accomplished through robust intellectual property (IP) safeguards, and the requirement to guarantee inexpensive availability of vital medications during a pandemic. The equilibrium between these two essential principles is exceptionally fragile, especially within the framework of a worldwide health emergency.

International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

India's stance on compulsory licensing can be seen as a response to this tension. While the issuance of compulsory licences can limit the profitability of pharmaceutical companies holding patents, India argues that the flexibility to issue such licences is a necessary tool to ensure access to life-saving treatments. It is essential to strike a balance that promotes innovation while preventing patent holders from exploiting their monopoly to the detriment of public health.

F. Global Supply Chains and Knowledge Transfer

One of the challenges India faces as it contributes to global pandemic response is the intricacy of global supply chains for vaccine and drug production[xxxvii]. Ensuring access to medical solutions during a pandemic often involves transferring not only finished products but also knowledge, technology, and raw materials. This transfer is critical for rapidly scaling up production to meet the demands of a global health crisis.

The pandemic has exposed vulnerabilities in global supply chains, highlighting the importance of secure access to essential raw materials, quality control measures, and manufacturing capacity. India's perspective underscores the role of IP in facilitating or hindering these transfers. For example, the availability of knowledge and technology transfer, often secured through licensing agreements, is essential to enable other countries or manufacturers to produce vaccines and treatments[xxxviii].

India's experience as a vaccine manufacturer and its role in producing vaccines under licensing agreements with other companies, such as AstraZeneca's Covishield, exemplify the importance of facilitating the transfer of knowledge and technology. The challenge lies in ensuring that IP rights do not act as barriers to this transfer, particularly when there is an urgent need for rapid production[xxxix].

Although the TRIPS Agreement provides flexibility in the context of public health emergency, there are still uncertainties over the actual execution of these measures. India's perspective in facilitating knowledge transfer and the production of vaccines and treatments highlights the importance of creating mechanisms that promote cooperation between countries and pharmaceutical companies for the greater good during pandemics.

VI. Critical Analysis Of The Indian Perspective On Intellectual Property And Pandemic Response

The Indian perspective on intellectual property (IP) and pandemic response presents a unique and multifaceted approach to addressing the complex relationship between IP rights and global public health.

India's pharmaceutical industry, history of compulsory licensing, active participation in international collaborations, and leadership in vaccine development all reflect a commitment to ensuring equitable access to essential medicines. Nevertheless, as the country manages the COVID-19 crisis and interacts with international partners, it encounters favourable circumstances and difficulties that require careful examination.

India's pharmaceutical industry is a pillar of strength in the nation's approach to pandemics. The sector's extensive manufacturing capabilities, coupled with a well-established global supply chain, have positioned India as a major player in producing affordable generic medicines and vaccines. This role has been pivotal in providing timely and cost-effective healthcare solutions during the pandemic, exemplifying the nation's potential to contribute to global public health[xl].

India's experience with compulsory licensing, exemplified by the case of Bayer's Nexavar, showcases the nation's commitment to balancing IP protection and public health needs. Compulsory licensing has been a crucial tool in ensuring access to life-saving treatments at a fraction of the cost charged by originator companies. While India has not yet issued compulsory licences for COVID-19 products, its legal framework provides the flexibility to do so when necessary[xli]. India's active engagement in international collaborations and access initiatives is a testament to its commitment to global public health. The nation's participation in the World Health Organization's (WHO) COVAX initiative and its role in vaccine development exemplify India's dedication to making essential medical solutions accessible worldwide. This perspective aligns with the idea that access to vaccines and treatments should be regarded as a global public good, especially during a pandemic[xlii].

The issue of "vaccine nationalism" has underscored the challenges India faces in its pursuit of equitable access to medical solutions[xliii]. In a world grappling with the pandemic, some countries have prioritised securing vaccines for their own populations over global cooperation. This approach can hinder international collaboration and disrupt the fair distribution of vaccines. India's efforts to provide vaccines to other countries must navigate this complex terrain of nationalism and global solidarity.

India's approach to balancing IP protection with the need for public health imperatives has been met with criticism from multinational pharmaceutical companies[xliv]. The utilization of compulsory licensing and the implementation of certain patent challenges have sparked apprehensions over their effect on innovation and investment within the pharmaceutical industry.

International Journal of Recent Development in Engineering and Technology
Website: www.ijrdet.com (ISSN 2347-6435(Online) Volume 15, Issue 01, January 2026)

The discussion underscores the conflict between safeguarding intellectual property rights and guaranteeing availability of vital medications in the midst of a pandemic. While India' pharmaceutical industry has the capacity to manufacture affordable medicines at scale, certain challenges must be addressed. These include securing the necessary raw materials, ensuring quality control, and meeting increased global demand. The pandemic has exposed vulnerabilities in the global supply chain, raising questions about the role of IP in facilitating or hindering the transfer of knowledge and technology for vaccine and drug production[xlv].

India' perspective on IP and pandemic response extends far beyond its borders. The nation' contributions, particularly in the area of vaccine production, have had a global impact. As India manufactures millions of doses of COVID-19 vaccines, it contributes to bridging the global vaccination gap. This has the capacity to potentially save an infinite number of lives, particularly in nations with lower and intermediate incomes where the availability of vaccines has been restricted. Furthermore, India's position on mandatory licensing has established a standard for other nations contemplating comparable measures to guarantee availability of vital medications. The experience of the Nexavar case in 2012 and India's existing legal framework for compulsory licensing underscore the importance of a flexible IP regime that can be adapted during public health emergencies. This perspective aligns with the World Trade Organization's TRIPS Agreement, which allows for such flexibility in cases of public health emergencies[xlvi].

VII. The Way Forward for India

India's stance on intellectual property (IP) and pandemics demonstrates a dedication to worldwide public health and fair availability of crucial medications. The nation's robust pharmaceutical industry, experience with compulsory licensing, active involvement in international collaborations, and leadership in vaccine development all contribute to a vision of shared responsibility and solidarity. As India continues to navigate the COVID-19 pandemic and prepares for future global health crises, it faces the challenge of maintaining a delicate balance between protecting IP rights and addressing public health imperatives. The nation must remain vigilant in advocating for equitable access to medical solutions while actively engaging with international stakeholders and addressing concerns surrounding vaccine nationalism and the potential impact on innovation and investment in the pharmaceutical sector.

In conclusion, India's perspective on IP and pandemic response underscores the importance of global collaboration and a balanced approach to ensure that essential medical innovations are accessible to all, regardless of their economic status or geographic location. The nation's contributions have already had a significant impact on global public health, making it an essential player in the collective effort to combat the COVID-19 pandemic and future health crises.

VIII. Conclusion

The meaning and concept of intellectual property in the context of a pandemic encapsulates both the advantages and challenges of IP protection in the realm of public health. While IP incentivizes innovation, fosters collaboration, and maintains quality control, it must be balanced with the need for equitable access to medical solutions during a global health crisis.

The challenges brought to the fore by the COVID-19 pandemic, including issues of access, vaccine nationalism, and the necessity of emergency measures, highlight the complex interplay between IP and public health. International agreements and organisations, such as TRIPS and the WHO, provide a framework for addressing these challenges, emphasising the importance of striking a balance between IP rights and the urgency of public health imperatives during a pandemic.

The international scenario regarding intellectual property and pandemics underscores the need for a collaborative and balanced approach to address the challenges posed by a global health crisis. International agreements, organisations like the WHO, and collaborative initiatives aim to ensure equitable access to medical solutions while recognizing the importance of IP protection.

The COVID-19 pandemic has highlighted the intricacies of managing intellectual property rights in conjunction with public health priorities. In order to protect global public health, it is crucial for countries to work together and demonstrate a collective dedication to tackling intellectual property (IP) matters amidst the ongoing pandemic and future health emergencies.

India's perspective on IP and pandemics is rooted in its commitment to global public health. The nation's pharmaceutical industry and regulatory framework have played a pivotal role in producing generic medicines and enabling the issuance of compulsory licences when necessary. India actively engages in international collaborations and access initiatives, exemplified by its involvement in the COVAX initiative and leadership in vaccine development.

As the world continues to navigate the COVID-19 pandemic and prepare for future global health crises, India's perspective serves as a testament to the need for a balanced approach to IP protection and public health. It emphasises that the global community must work together to ensure that essential medical innovations are accessible to all, regardless of their economic status or geographic location.

REFERENCES

[1] "ACT-Accelerator COVID-19", World Health Organization, https://www.who.int/initiatives/act-accelerator (last visited Sep 25, 2023).

[2] "Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)" World Trade Organization, https://www.wto.org/english/docs_e/legal_e/27-trips.pdf. (last visited Sep 27, 2023).

[3] "Compulsory licensing of patented pharmaceuticals: a solution to access and affordability?" The Guardian, https://www.theguardian.com/science/political-science/2016/sep/23/compulsory-licensing-of-patented-pharmaceuticals-a-solution-to-access-and-affordability (last visited Sep 27, 2023)

[4] "COVAX: Working for global equitable access to COVID-19 vaccines", World Health Organization, https://www.who.int/initiatives/act-accelerator/covax (last visited Sep 25, 2023)

[5] "COVID-19 Technology Access Pool (C-TAP)", World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON250 (last visited Sep 25, 2023)

[6] "COVID-19 Vaccine Update - India Ministry of Health and Family Welfare", Government of India, https://main.mohfw.gov.in/covid_vaccination/vaccination/index.html . (last visited Sep 27, 2023)

[7] "Doha Declaration on the TRIPS Agreement and Public Health", WTO, https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm (last visited Sep 25, 2023)

[8] "India Issues First Compulsory License Ministry of Commerce &amp", Industry, Government of India, https://pib.gov.in/newsite/erelease.aspx?relid=81071. (last visited Sep 27, 2023)

[9] "Indian Pharmaceutical Industry: A Review National Council of Applied", Economic Research, https://www.ncaer.org/publication_details.php?pID=234. (last visited Sep 27, 2023)

[10] "Intellectual property and COVID-19", World Trade Organization, https://www.wto.org/ english/tratop_e/covid19_e/ip_waiver_info_e.htm (last visited Sep 25, 2023)

[11] "Local production of pharmaceuticals and medical technologies: a roadmap to strengthening local production", World Health Organization, https://www.who.int/publications/i/item/ 978924002208. (last visited Sep 25, 2023)

[12] "Patent basics United States Patent and Trademark Office - An Agency of the Department of Commerce", https://www.uspto.gov/patents/basics (last visited Sep 25, 2023)

[13] "Patents and competition in the pharmaceutical industry: The future of access to essential medicines," , https:// journals.sagepub.com/doi/10.12927/whp.2016.24840 (last visited Sep 25, 2023)

[14] "Pharma industry raises pressure on India over patents" Financial Times, https:// www.ft.com/content/3ea189fb-2edf-487d-9077-e68f9d3923f8 (last visited Sep 27, 2023).

[15] "Trade secret law", Justia, https://www.justia.com/intellectual-property/trade-secrets/ (last visited Sep 25, 2023)

[16] "Trademarks and Brands", WIPO, https://www.wipo.int/trademarks/en/. (last visited Sep 25, 2023)

[17] "Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19", World Trade Organization, https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True (last visited Sep 25, 2023).

[18] "What is intellectual property (IP)?" WIPO, https://www.wipo.int/about-ip/en/. (last visited Sep 26, 2023)

[19] "WHO's role in the COVID-19 response", World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON250 (last visited Sep 25, 2023)

[20] "Why India's Decision to Issue a Compulsory Licence for Nexavar Matters", The Wire, https://thewire.in/health/natco-compulsory-licence-nexavar-bayer (last visited Sep 27, 2023)

[21] Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) World Trade Organization, https://www.wto.org/english/docs_e/legal_e/27-trips.pdf (last visited Sep 25, 2023)

[22] D.A. Matthews & A. K. Liang, "Deal-Making over Data: The Health Data Use Coalition and the Limits of Data Access in the U.S.,", The American Journal of Bioethics (2018)

[23] India begins supply of COVID-19 vaccines to Africa under COVAX facility The Indian Express, https://indianexpress.com/article/india/india-begins-supply-of-covid-19-vaccines- to-africa-under-covax-facility-7207487/. (last visited Sep 27, 2023)

[24] J. Kanavos, "The rising burden of COVID-19, patent rights, and the necessity of compulsory licensing," , The Lancet (2020)

[25] M. Kremer & R. Glenn Hubbard, "Policies to Advance Innovation," Science, 2018, , OCED (2018).

[26] A. Matthews & amp; A. K. Liang, "Deal-Making over Data: The Health Data Use Coalition and the Limits of Data Access in the U.S.," , The American Journal of Bioethics (2018)

[27] United States Copyright Office, "Copyright Basics," https://www.copyright.gov/circs/circ01.pdf (last visited Sep 24, 2023)

[28] United States Patent and Trademark Office United States Patent and Trademark Office - An Agency of the Department of Commerce, https://www.uspto.gov/ (last visited Sep 28, 2023)

[29] United States Patent and Trademark Office, "General Information Concerning Patents" United States Patent and Trademark Office - An Agency of the Department of Commerce, http://uspto.gov/ (last visited Sep 23, 2023)

[30] WTO reports on Covid-19 and World Trade WTO, https://www.wto.org/english/tratop_e/covid19_e/covid_reports_e.html. (last visited Sep 25, 2023)

[i] "What is intellectual property (IP)?" WIPO, https://www.wipo.int/about-ip/en/. (last visited Sep 26, 2023)
[ii] United States Patent and Trademark Office, "General Information Concerning Patents" United States Patent and Trademark Office - An Agency of the Department of Commerce, http://uspto.gov/ (last visited Sep 23, 2023)
[iii] United States Copyright Office, "Copyright Basics," https://www.copyright.gov/circs/circ01.pdf (last visited Sep 24, 2023)
[iv] United States Patent and Trademark Office United States Patent and Trademark Office - An Agency of the Department of Commerce, https://www.uspto.gov/ (last visited Sep 28, 2023)
[v] "Trade secret law", Justia, https://www.justia.com/intellectual-property/trade-secrets/ (last visited Sep 25, 2023)
[vi] M. Kremer & R. Glenn Hubbard, "Policies to Advance Innovation," Science, 2018, , OCED (2018).
[vii] J. Kanavos, "The rising burden of COVID-19, patent rights, and the necessity of compulsory licensing," , The Lancet (2020)
[viii] "Trademarks and Brands", WIPO, https://www.wipo.int/trademarks/en/. (last visited Sep 25, 2023)
[ix] "Patent basics United States Patent and Trademark Office - An Agency of the Department of Commerce", https://www.uspto.gov/patents/basics (last visited Sep 25, 2023)
[x] D.A. Matthews & A. K. Liang, "Deal-Making over Data: The Health Data Use Coalition and the Limits of Data Access in the U.S.,", The American Journal of Bioethics (2018)
[xi] A. Matthews & amp; A. K. Liang, "Deal-Making over Data: The Health Data Use Coalition and the Limits of Data Access in the U.S.," , The American Journal of Bioethics (2018)
[xii] WTO reports on Covid-19 and World Trade WTO, https://www.wto.org/english/tratop_e/covid19_e/covid_reports_e.htm (last visited Sep 25, 2023)
[xiii] "Patents and competition in the pharmaceutical industry: The future of access to essential medicines," , https:// journals.sagepub.com/doi/10.12927/whp.2016.24840 (last visited Sep 25, 2023)
[xiv] Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) World Trade Organization, https://www.wto.org/english/docs_e/legal_e/27-trips.pdf (last visited Sep 25, 2023)
[xv] "Doha Declaration on the TRIPS Agreement and Public Health", WTO, https://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm (last visited Sep 25, 2023)
[xvi] "WHO's role in the COVID-19 response", World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON250 (last visited Sep 25, 2023)
[xvii] Supra Note 14.
[xviii] Supra Note 15.
[xix] Supra Note 16.
[xx] "COVAX: Working for global equitable access to COVID-19 vaccines", World Health Organization, https://www.who.int/initiatives/act-accelerator/covax (last visited Sep 25, 2023)
[xxi] "ACT-Accelerator COVID-19", World Health Organization, https://www.who.int/initiatives/act-accelerator (last visited Sep 25, 2023).
[xxii] "COVID-19 Technology Access Pool (C-TAP)", World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON250 (last visited Sep 25, 2023)
[xxiii] "Waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19", World Trade Organization, https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/IP/C/W669.pdf&Open=True (last visited Sep 25, 2023).
[xxiv] Supra Note 11.
[xxv] "Intellectual property and COVID-19", World Trade Organization, https://www.wto.org/ english/tratop_e/covid19_e/ip_waiver_info_e.htm (last visited Sep 25, 2023)
[xxvi] "Local production of pharmaceuticals and medical technologies: a roadmap to strengthening local production", World Health Organization, https://www.who.int/publications/i/item/ 978924002208. (last visited Sep 25, 2023)
[xxvii] "Indian Pharmaceutical Industry: A Review National Council of Applied", Economic Research, https://www.ncaer.org/publication_details.php?pID=234. (last visited Sep 27, 2023)
[xxviii] India begins supply of COVID-19 vaccines to Africa under COVAX facility The Indian Express, https://indianexpress.com/article/india/india-begins-supply-of-covid-19-vaccines- to-africa-under-covax-facility-7207487/. (last visited Sep 27, 2023)
[xxix] "Why India's Decision to Issue a Compulsory Licence for Nexavar Matters", The Wire, https://thewire.in/health/natco-compulsory-licence-nexavar-bayer (last visited Sep 27, 2023)
[xxx] "India Issues First Compulsory License Ministry of Commerce &amp", Industry, Government of India,

https://pib.gov.in/newsite/erelease.aspx?relid=81071. (last visited Sep 27, 2023)

[xxxi] Supra Note 20.

[xxxii] Supra Note 28.

[xxxiii] "COVID-19 Vaccine Update - India Ministry of Health and Family Welfare", Government of India, https://main.mohfw.gov.in/covid_vaccination/vaccination/index.html. (last visited Sep 27, 2023)

[xxxiv] Supra Note 11.

[xxxv] "Pharma industry raises pressure on India over patents" Financial Times, https:// www.ft.com/content/3ea189fb-2edf-487d-9077-e68f9d3923f8 (last visited Sep 27, 2023).

[xxxvi] "Compulsory licensing of patented pharmaceuticals: a solution to access and affordability?" The Guardian, https://www.theguardian.com/science/political-science/2016/sep/23/ compulsory-licensing-of-patented-pharmaceuticals-a-solution-to-access-and-affordability (last visited Sep 27, 2023)

[xxxvii] Supra Note 26.

[xxxviii] Supra Note 14.

[xxxix] Supra Note 20.

[xl] Supra Note 27.

[xli] Supra Note 30.

[xlii] Supra Note 20.

[xliii] Supra Note 11.

[xliv] Supra Note 35.

[xlv] Supra Note 26.

[xlvi] "Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)" World Trade Organization, https://www.wto.org/english/docs_e/legal_e/27-trips.pdf. (last visited Sep 27, 2023).